Hao X P, Wu S, Jiang Z F
Department of General Surgery, First Medical Center of People's Liberation Army General Hospital, Beijing 100853, China.
Department of Oncology, Fifth Medical Center of People's Liberation Army General Hospital, Beijing 100071, China.
Zhonghua Wai Ke Za Zhi. 2025 Aug 1;63(8):682-689. doi: 10.3760/cma.j.cn112139-20241012-00459.
With the advancement of precision medicine, the treatment of early-stage breast cancer is gradually moving toward standardized individualization. While ensuring therapeutic efficacy, increasing attention is being given to patients' quality of life. In recent years, as clinical research data on targeted therapies for HER2-positive breast cancer, CDK4/6 inhibitors for hormone receptor-positive breast cancer, and immune checkpoint inhibitors for triple-negative breast cancer have accumulated, the treatment of early-stage breast cancer has become more precise and personalized. Furthermore, the growing body of clinical research on breast-conserving surgery, axillary preservation, and even the omission of primary tumor resection has significantly improved patients' quality of life. These more effective drugs and advanced technologies provide the foundation for de-escalation treatment strategies in early-stage breast cancer, driving the development of a more refined, patient-centered treatment approach.
随着精准医学的发展，早期乳腺癌的治疗正逐渐走向标准化的个体化。在确保治疗效果的同时，患者的生活质量也越来越受到关注。近年来，随着HER2阳性乳腺癌靶向治疗、激素受体阳性乳腺癌CDK4/6抑制剂以及三阴性乳腺癌免疫检查点抑制剂的临床研究数据不断积累，早期乳腺癌的治疗变得更加精准和个性化。此外，关于保乳手术、腋窝保留甚至省略原发肿瘤切除的临床研究不断增加，显著提高了患者的生活质量。这些更有效的药物和先进技术为早期乳腺癌的降阶梯治疗策略提供了基础，推动了更精细化、以患者为中心的治疗方法的发展。
